XVIPF (Xvivo Perfusion AB) EPS without NRI: $0.25 (TTM As of Mar. 2026)


XVIPF Xvivo Perfusion AB XVIPF
91 GF Score
Price $29.00
GF Value $42.07
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB EPS without NRI?

Xvivo Perfusion AB XVIPF -1.32% 91 EPS without NRI is $0.25 as of Mar. 2026. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.07 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 667 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 51.27% on this metric.

Xvivo Perfusion AB's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $0.12. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.

During the past 12 months, Xvivo Perfusion AB's average earnings per share (NRI) Growth Rate was -45.70% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 8.80% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Xvivo Perfusion AB's EPS without NRI or its related term are showing as below:

XVIPF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -42.6   Med: 17.4   Max: 168.9
Current: 8.8

During the past 13 years, Xvivo Perfusion AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 168.90% per year. The lowest was -42.60% per year. And the median was 17.40% per year.

XVIPF's 3-Year EPS without NRI Growth Rate is ranked better than
51.27% of 667 companies
in the Medical Devices & Instruments industry
Industry Median: 8.2 vs XVIPF: 8.80

Xvivo Perfusion AB's EPS (Diluted) for the three months ended in Mar. 2026 was $0.12. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.

Xvivo Perfusion AB's EPS (Basic) for the three months ended in Mar. 2026 was $0.12. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $0.25.


Xvivo Perfusion AB  (OTCPK:XVIPF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Xvivo Perfusion AB EPS without NRI Related Terms


Xvivo Perfusion AB EPS without NRI Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB EPS without NRI Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.06 0.30 0.50 0.09

Xvivo Perfusion AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 0.01 0.02 0.11 0.12

XVIPF vs ABT, SYK, MDT: EPS without NRI Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's PE Ratio without NRI falls into.


XVIPF
91GF Score
Xvivo Perfusion AB XVIPF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $0.25 mean?
Xvivo Perfusion AB (XVIPF) has a EPS without NRI of $0.25 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #325 out of 667 companies in the Medical Devices & Instruments industry, placing it in the top 48.7%.
Is Xvivo Perfusion AB's EPS without NRI too high?
Xvivo Perfusion AB's current EPS without NRI is $0.25. The Medical Devices & Instruments industry median EPS without NRI is 8.20. Xvivo Perfusion AB's value of $0.25 is 97% below this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #325 out of 667 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #325 out of 667 companies for EPS without NRI. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median EPS without NRI is 8.20. Xvivo Perfusion AB's value of $0.25 is 97% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.20, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current EPS without NRI of $0.25 is 97% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current EPS without NRI is $0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.07, compared to a current price of $29.00 — trading 31.1% below its estimated fair value. The current EPS without NRI is $0.25 and 97% below the Medical Devices & Instruments industry median of 8.20. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current EPS without NRI is $0.25 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of $29.00 is trading 31.1% below its estimated GF Value™ of $42.07. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for XVIPF:

  • EPS without NRI: $0.25
  • GF Value™: $42.07 vs. price of $29.00 (31.1% below fair value)
  • GF Score™: 91/100 with 2 warning signs
  • Industry Position: 97% below the Medical Devices & Instruments median (#325 of 667)

No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score

Get the complete analysis for XVIPF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.00
Price
$42.07
GF Value